- Home
- TELA
TELA
TELA Bio Inc.
as 12-18-2024 11:43am EST
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 61.8M | IPO Year: | 2019 |
| Target Price: | $9.25 | AVG Volume (30 days): | 132.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $7.84 | Next Earning Date: | 11-07-2024 |
| Revenue: | $68,649,000 | Revenue Growth: | 29.34% |
| Revenue Growth (this year): | 30.39% | Revenue Growth (next year): | 25.51% |
Stock Insider Trading Activity of TELA Bio Inc. (TELA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Firestone Gregory A. | TELA | Chief Commercial Officer | Oct 24 '24 | Buy | $2.25 | 6,666 | $14,998.50 | 57,279 | |
| KOBLISH ANTONY | TELA | Chief Executive Officer | Oct 24 '24 | Buy | $2.25 | 88,888 | $199,998.00 | 458,897 | |
| Talmo Paul | TELA | Chief Technology Officer | Oct 24 '24 | Buy | $2.25 | 22,222 | $49,999.50 | 91,082 | |
| Cuca Roberto | TELA | COO and CFO | Oct 24 '24 | Buy | $2.25 | 64,444 | $144,999.00 | 155,388 |
Latest TELA Bio Inc. News
TELA Breaking Stock News: Dive into TELA Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
17 days ago
The past five years for TELA Bio (NASDAQ:TELA) investors has not been profitable
GlobeNewswire
a month ago
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
Simply Wall St.
a month ago
TELA Bio Third Quarter 2024 Earnings: EPS Beats Expectations
Thomson Reuters StreetEvents
a month ago
Q3 2024 TELA Bio Inc Earnings Call
GuruFocus.com
a month ago
TELA Bio Inc (TELA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Zacks
a month ago
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
TELA Bio Reports Third Quarter 2024 Financial Results
Compare TELA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TELA TELA Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.